Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing life-saving medicines, has announced its participation in the upcoming JonesTrading Virtual Precision Medicine Symposium. Mike Andriole, CEO, and Tom Riga, Chief Operating and Commercial Officer, will engage in a fireside chat on Monday, February 3, 2025, at 11:00 a.m. ET.
The presentation will be accessible via audio webcast through the Investor Relations section of Chimerix's website at ir.chimerix.com. The recording will remain available for approximately 90 days following the event.
Chimerix (NASDAQ: CMRX), un'azienda biofarmaceutica concentrata sullo sviluppo di medicinali salvavita, ha annunciato la sua partecipazione al prossimo Simposio Virtuale sulla Medicina di Precisione di JonesTrading. Mike Andriole, CEO, e Tom Riga, Direttore Operativo e Commerciale, parteciperanno a una chiacchierata informale lunedì 3 febbraio 2025, alle 11:00 ET.
La presentazione sarà accessibile tramite audio webcast nella sezione Relazioni con gli Investitori del sito web di Chimerix all'indirizzo ir.chimerix.com. La registrazione rimarrà disponibile per circa 90 giorni dopo l'evento.
Chimerix (NASDAQ: CMRX), una empresa biofarmacéutica centrada en el desarrollo de medicamentos que salvan vidas, ha anunciado su participación en el próximo Símbolo Virtual de Medicina de Precisión de JonesTrading. Mike Andriole, CEO, y Tom Riga, Director de Operaciones y Comercial, participarán en una charla informal el lunes 3 de febrero de 2025, a las 11:00 a.m. ET.
La presentación estará disponible a través de un audio webcast en la sección de Relaciones con Inversores del sitio web de Chimerix en ir.chimerix.com. La grabación estará disponible durante aproximadamente 90 días después del evento.
Chimerix (NASDAQ: CMRX), 생명을 구하는 약물을 개발하는 데 집중하는 생명공학 회사가 JonesTrading 가상 정밀 의학 심포지엄에 참석한다고 발표했습니다. Mike Andriole CEO와 Tom Riga 최고 운영 및 상업 책임자가 2025년 2월 3일 월요일 오전 11시 ET에 대담을 진행합니다.
프레젠테이션은 Chimerix 웹사이트의 투자자 관계 섹션을 통해 오디오 웹캐스트를 통해 접근할 수 있습니다. 녹음은 이벤트 이후 약 90일 동안 제공될 예정입니다.
Chimerix (NASDAQ: CMRX), une entreprise biopharmaceutique axée sur le développement de médicaments salvateurs, a annoncé sa participation au prochain Symposium Virtuel sur la Médecine de Précision de JonesTrading. Mike Andriole, PDG, et Tom Riga, Directeur des Opérations et Commercial, participeront à une discussion informelle le lundi 3 février 2025, à 11h00 ET.
La présentation sera accessible via un webinaire audio dans la section des Relations Investisseurs du site internet de Chimerix à l'adresse ir.chimerix.com. L'enregistrement restera disponible pendant environ 90 jours après l'événement.
Chimerix (NASDAQ: CMRX), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von lebensrettenden Medikamenten konzentriert, hat seine Teilnahme am bevorstehenden JonesTrading Virtuellen Symposium zur Präzisionsmedizin bekannt gegeben. Mike Andriole, CEO, und Tom Riga, Chief Operating and Commercial Officer, werden am Montag, den 3. Februar 2025, um 11:00 Uhr ET an einem informellen Gespräch teilnehmen.
Die Präsentation wird über ein Audio-Webcast im Bereich Investor Relations der Chimerix-Website unter ir.chimerix.com zugänglich sein. Die Aufzeichnung wird etwa 90 Tage nach der Veranstaltung verfügbar bleiben.
- None.
- None.
DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on Monday, February 3, 2025 at 11:00 a.m. ET.
An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone, is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
INVESTOR CONTACT:
Will O’Connor
Stern Investor Relations
will.oconnor@sternir.com
MEDIA CONTACT:
Dana Davis
Steelwire
dana@steelwire.co
FAQ
When is Chimerix (CMRX) presenting at the JonesTrading Virtual Precision Medicine Symposium?
How can investors access Chimerix's (CMRX) presentation at the JonesTrading Symposium?
How long will Chimerix's (CMRX) JonesTrading Symposium presentation be available online?
Which Chimerix (CMRX) executives are participating in the JonesTrading Symposium?
